The Biotech Growth Trust PLC - London-based investment trust - Says on Friday, May 1 that its investee, Esperion Therapeutics, will be acquired by ArchiMed SAS, a Lyon, France-based private equity firm. BIOG calls Esperion "a US-based commercial biopharmaceutical company focused on drugs targeting cardiovascular diseases." BIOG notes that its pre-announcement stake in Esperion represents 2.5% of BIOG's net asset value. The transaction was priced at USD3.16 per share, or approximately USD1.00 billion, with an additional USD100 million contingent on Esperion's upcoming sales performance.
Current stock price: 1,336.00 pence, closing up 2.5% in London on Tuesday.
12-month change: up 80%
By John Robaina, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.



